Yüklüyor......
P08.32 TG02, an oral CDK inhibitor, demonstrates activity in glioma models: EORTC Brain Tumor Group Conducts Phase 1b study (STEAM / EORTC 1608)
Introduction TG02 is an orally-bioavailable, multi-kinase inhibitor. Its primary anti-tumor mechanism of action is through CDK9-dependent depletion (IC50 = 3nM) of oncoproteins such as Mcl-1 and MYC. TG02 also strongly inhibits CDK5 (IC50 = 4nM). MYC, Mcl-1 and CDK5 are frequently overexpressed in g...
Kaydedildi:
| Yayımlandı: | Neuro Oncol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782661/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.165 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|